SCTC21C
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 14, 2025
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
(clinicaltrials.gov)
- P1/2 | N=99 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P1/2 trial • Glomerulonephritis • IgA Nephropathy • Immunology • Renal Disease
April 22, 2024
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=74 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology
February 09, 2024
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=74 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
1 to 3
Of
3
Go to page
1